GlassScriptPhysician profile
Virginia C Hall
NPI 1073501276
$9,367.32
in general payments reported to CMS, 2019-2025
35 companies · $1,610 in 2025
The $1,610 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $659 · 2020: $700 · 2021: $1,215 · 2022: $2,133 · 2023: $1,114 · 2024: $1,936 · 2025: $1,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,384 · Education: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,384.48 |
| Education | $275.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,953.10 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $928.31 | 2021-2025 | Libtayo, Dupixent |
| Sun Pharmaceutical Industries INC. | $926.28 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Incyte Corporation | $847.23 | 2021-2025 | Opzelura, Opzelura |
| Ucb, INC. | $831.14 | 2021-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $754.53 | 2019-2025 | |
| Janssen Biotech, INC. | $518.27 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $460.46 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Genzyme Corporation | $333.10 | 2019-2024 | |
| Arcutis Biotherapeutics, INC. | $261.96 | 2023-2025 | Zoryve |
| Pfizer INC. | $230.73 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $202.79 | 2019-2024 | |
| Galderma Laboratories, L.P. | $169.60 | 2019-2025 | Aklief, Nemluvio |
| Journey Medical Corporation | $152.40 | 2019-2025 | |
| Kyowa Kirin, INC. | $135.37 | 2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $92.57 | 2019-2025 | Cabtreo, Jublia, Siliq |
| Leo Pharma INC. | $82.91 | 2019-2022 | |
| Amgen INC. | $60.26 | 2020-2022 | |
| Almirall LLC | $55.06 | 2023-2024 | Seysara |
| Dermavant Sciences, INC. | $47.71 | 2023-2024 | Vtama |
| Merz North America, INC. | $36.04 | 2020-2021 | |
| Prugen, INC. Pharmaceuticals | $36.02 | 2019-2020 | |
| Fidia Pharma USA INC. | $35.87 | 2024-2025 | Triluron, Hymovis, Hyalgan |
| Paratek Pharmaceuticals, INC. | $34.61 | 2021-2024 | Nuzyra |
| Sebela Pharmaceuticals INC. | $32.35 | 2019 | |
| Vyne Pharmaceuticals INC. | $19.03 | 2020 | |
| Biofrontera INC. | $17.32 | 2022 | |
| Dusa Pharmaceuticals, INC. | $16.73 | 2019 | |
| Dermira, INC. | $15.76 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $15.73 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.69 | 2024 | Spevigo |
| Medline Industries LP | $13.55 | 2023 | |
| Mission Pharmacal Company | $13.47 | 2019 | |
| Merck Sharp & Dohme LLC | $12.26 | 2019 | |
| Allergan, INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virginia Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.